Leerink Partnrs Has Bearish Forecast for SCPH Q2 Earnings

scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for scPharmaceuticals in a research report issued on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings per share of ($0.37) for the quarter, down from their previous forecast of ($0.31). The consensus estimate for scPharmaceuticals' current full-year earnings is ($1.53) per share. Leerink Partnrs also issued estimates for scPharmaceuticals' Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($0.70) EPS.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). The company had revenue of $11.75 million for the quarter, compared to analyst estimates of $11.63 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%.

A number of other research analysts have also recently weighed in on SCPH. Maxim Group dropped their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, March 20th.

scPharmaceuticals Price Performance

SCPH stock traded down $0.23 during midday trading on Monday, hitting $3.29. 481,632 shares of the stock were exchanged, compared to its average volume of 368,746. The stock's 50-day moving average price is $2.62 and its 200-day moving average price is $3.15. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The stock has a market cap of $173.69 million, a price-to-earnings ratio of -1.73 and a beta of 0.17. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $5.65.

Institutional Investors Weigh In On scPharmaceuticals

A number of large investors have recently bought and sold shares of SCPH. Cubist Systematic Strategies LLC purchased a new stake in shares of scPharmaceuticals in the first quarter valued at $76,000. Apis Capital Advisors LLC raised its stake in scPharmaceuticals by 28.2% in the 1st quarter. Apis Capital Advisors LLC now owns 504,947 shares of the company's stock valued at $1,328,000 after purchasing an additional 110,947 shares during the last quarter. Kingdon Capital Management L.L.C. lifted its holdings in scPharmaceuticals by 25.0% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,000,000 shares of the company's stock valued at $2,630,000 after purchasing an additional 200,000 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of scPharmaceuticals during the 1st quarter worth about $2,413,000. Finally, Comerica Bank boosted its stake in shares of scPharmaceuticals by 22.1% during the 1st quarter. Comerica Bank now owns 38,662 shares of the company's stock worth $102,000 after purchasing an additional 7,000 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company's stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.